Proceeds to accelerate therapeutic programs and deepen company pipeline Investment underscores unmet global needs for novel retinal medicines Kodiak Sciences Inc., a biopharmaceutical company designing and developing novel therapies for the treatment of retinal disease, announced today the closing of a $34 million Series B financing. The round was led by a U.S.-based life sciences-focused … Continued

Company emerges with a potentially disruptive retinal pipeline Kodiak Sciences Inc., a biopharmaceutical company founded in 2009 as Oligasis LLC, announced the launch of its new corporate identity. The company’s new identity reflects the maturation of the company’s product pipeline and highlights the company’s commitment to building a durable, independent ophthalmology franchise for the benefit of patients globally. For more … Continued